8.71MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Akari Therapeutics PLC
Currency: USD Updated: 2025-10-27 Key Insights
Its valuation is considered fairly valued, Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at max_target_price.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Akari Therapeutics PLC's Score
Score Analysis
Current score
Previous score
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Akari Therapeutics PLC Highlights
StrengthsRisks
Financial Health
Currency: USD Updated: 2025-10-27 No financial score is currently available for Akari Therapeutics PLC. The Pharmaceuticals industry's average is 7.77.
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Key Metrics
Total revenue
Operating profit
Total assets
SG&A
Relevant data have not been disclosed by the company yet.
Key Metrics
Cash flow from operating activities
Income after tax
Relevant data have not been disclosed by the company yet.
Key Metrics
Cash flow from operating activities
Total revenue
Relevant data have not been disclosed by the company yet.
Key Metrics
Relevant data have not been disclosed by the company yet.
Akari Therapeutics PLC's Company Valuation
Currency: USD Updated: 2025-10-27The current valuation score of Akari Therapeutics PLC is 7.49, ranking industry_rank/industry_total in the Pharmaceuticals industry. Its current P/E ratio is -3.31, which is -113.07% below the recent high of 0.43 and -47.30% above the recent low of -4.88.
Valuation Dimensions
Industry Ranking 131/173
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-10-27The current earnings forecast score of Akari Therapeutics PLC is 8.00, ranking industry_rank/industry_total in the Pharmaceuticals industry. The average price target for Akari Therapeutics PLC is 5.00, with a high of 7.00 and a low of 1.60.
Support & Resistance
Relevant data have not been disclosed by the company yet.
Strong Buy
Buy
Hold
Sell
Strong Sell
Akari Therapeutics PLC
AKTX
3
Vertex Pharmaceuticals Inc
VRTX
33
Financial Forecasting
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-10-27The current price momentum score of Akari Therapeutics PLC is 4.45, ranking industry_rank/industry_total in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 1.03 and the support level at 0.64, making it suitable for range-bound swing trading.
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Institutional Confidence
Currency: USD Updated: 2025-10-27The current institutional shareholding score of Akari Therapeutics PLC is 3.00, ranking industry_rank/industry_total in the Pharmaceuticals industry. The latest institutional shareholding proportion is 1.72%, representing a quarter-over-quarter decrease of 95.16%. The largest institutional shareholder is James Simons, holding a total of 17.41K shares, representing 0.05% of shares outstanding, with 44.78% decrease in holdings.
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Theofilos (Charles Steve)
Cresset Asset Management, LLC
Risk Assessment
Currency: USD Updated: 2025-10-27No risk assessment score is currently available for Akari Therapeutics PLC. The Pharmaceuticals industry's average is 5.11. The company's beta value is 0.34. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Beta vs S&P 500 index
0.27
240-Day Maximum Drawdown
+83.99%
240-Day Volatility
+139.50%
Volatility
Downside Risk-Adjusted Return
Maximum Daily Upside Volatility
Maximum Daily Downside Volatility
Akari Therapeutics PLC
AKTX
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mirum Pharmaceuticals Inc
MIRM
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Regeneron Pharmaceuticals Inc
REGN
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Collegium Pharmaceutical Inc
COLL
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
CPRX
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Akari Therapeutics PLC?
The TradingKey Stock Score provides a comprehensive assessment of Akari Therapeutics PLC based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Akari Therapeutics PLC’s performance and outlook.
How do we generate the financial health score of Akari Therapeutics PLC?
To generate the financial health score of Akari Therapeutics PLC, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Akari Therapeutics PLC's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Akari Therapeutics PLC.
How do we generate the company valuation score of Akari Therapeutics PLC?
To generate the company valuation score of Akari Therapeutics PLC, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Akari Therapeutics PLC’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Akari Therapeutics PLC’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Akari Therapeutics PLC.
How do we generate the earnings forecast score of Akari Therapeutics PLC?
To calculate the earnings forecast score of Akari Therapeutics PLC, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Akari Therapeutics PLC’s future.
How do we generate the price momentum score of Akari Therapeutics PLC?
When generating the price momentum score for Akari Therapeutics PLC, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Akari Therapeutics PLC’s prices. A higher score indicates a more stable short-term price trend for Akari Therapeutics PLC.
How do we generate the institutional confidence score of Akari Therapeutics PLC?
To generate the institutional confidence score of Akari Therapeutics PLC, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Akari Therapeutics PLC’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Akari Therapeutics PLC.
How do we generate the risk management score of Akari Therapeutics PLC?
To assess the risk management score of Akari Therapeutics PLC, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Akari Therapeutics PLC’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Akari Therapeutics PLC.
